Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes

Exclusion Criteria

• •History or family history of medullary thyroid carcinoma or MEN 2 syndrome;
• •History of chronic or acute pancreatitis;
• •Allergic to liraglutide or any components in Victoza®;
• •Hepatic abnormalities (transaminase \> 2 times normal);
• •Renal impairments (serum creatinine \>133 umol/L);
• •Cardiovascular diseases (hypertension, coronary heart disease, etc.);
• •Presence of anemia (Hb ≤100g/L), leukopenia (\<3.5×109/L);
• •Presence of disorder in coagulation or anticoagulation, or thrombocytopenia (platelets \<100×109/L);
• •Presence of acute metabolic disorders; In the case of acute ketone acidosis, with blood ketone over 0.3mmol/L and pH lower than 7.30;
• •Presence of any kind of chronic infection or immune deficiency, including hepatitis B, hepatitis C, HIV, syphilis or tuberculosis, etc.;
• •Chronic use of systemic glucocorticoids or other immunosuppressive agents for over 3 months;
• •Any history of malignancy;
• •Female patients who are pregnant or breastfeeding; any female who is unwilling to use a reliable and effective form of contraception for 2 years after recruitment;
• •Presence of any infectious diseases, including active skin infections, flu, fever, upper or lower respiratory tract infections; those who wish to participate in the study should keep the infection under control for at least 1 week before receiving Treg product infusion;
• •Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.